{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:27:51Z","timestamp":1791181671716,"version":"4.1.0"},"reference-count":96,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T00:00:00Z","timestamp":1380758400000},"content-version":"vor","delay-in-days":63,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Birth Defects Research Pt B"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:p>A metabolic biomarker\u2010based in vitro assay utilizing human embryonic stem (hES) cells was developed to identify the concentration of test compounds that perturbs cellular metabolism in a manner indicative of teratogenicity. This assay is designed to aid the early discovery\u2010phase detection of potential human developmental toxicants. In this study, metabolomic data from hES cell culture media were used to assess potential biomarkers for development of a rapid in vitro teratogenicity assay. hES cells were treated with pharmaceuticals of known human teratogenicity at a concentration equivalent to their published human peak therapeutic plasma concentration. Two metabolite biomarkers (ornithine and cystine) were identified as indicators of developmental toxicity. A targeted exposure\u2010based biomarker assay using these metabolites, along with a cytotoxicity endpoint, was then developed using a 9\u2010point dose\u2013response curve. The predictivity of the new assay was evaluated using a separate set of test compounds. To illustrate how the assay could be applied to compounds of unknown potential for developmental toxicity, an additional 10 compounds were evaluated that do not have data on human exposure during pregnancy, but have shown positive results in animal developmental toxicity studies. The new assay identified the potential developmental toxicants in the test set with 77% accuracy (57% sensitivity, 100% specificity). The assay had a high concordance (\u226575%) with existing in vivo models, demonstrating that the new assay can predict the developmental toxicity potential of new compounds as part of discovery phase testing and provide a signal as to the likely outcome of required in vivo tests.<\/jats:p>","DOI":"10.1002\/bdrb.21078","type":"journal-article","created":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T02:20:11Z","timestamp":1381544411000},"page":"343-363","source":"Crossref","is-referenced-by-count":93,"title":["Establishment and Assessment of a New Human Embryonic Stem Cell\u2010Based Biomarker Assay for Developmental Toxicity Screening"],"prefix":"10.1002","volume":"98","author":[{"given":"Jessica A.","family":"Palmer","sequence":"first","affiliation":[{"name":"Stemina Biomarker Discovery, Inc Madison Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan M.","family":"Smith","sequence":"additional","affiliation":[{"name":"Stemina Biomarker Discovery, Inc Madison Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Egnash","sequence":"additional","affiliation":[{"name":"Stemina Biomarker Discovery, Inc Madison Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Conard","sequence":"additional","affiliation":[{"name":"Stemina Biomarker Discovery, Inc Madison Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"West","sequence":"additional","affiliation":[{"name":"Stemina Biomarker Discovery, Inc Madison Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Burrier","sequence":"additional","affiliation":[{"name":"Stemina Biomarker Discovery, Inc Madison Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.R.","family":"Donley","sequence":"additional","affiliation":[{"name":"Stemina Biomarker Discovery, Inc Madison Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred R.","family":"Kirchner","sequence":"additional","affiliation":[{"name":"Stemina Biomarker Discovery, Inc Madison Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,10,3]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"Depacon [product information]","author":"AbbVie","year":"2013"},{"key":"e_1_2_6_3_1","unstructured":"ACToR database.2013.Web site. Available at:http:\/\/actor.epa.gov\/actor\/faces\/ACToRHome.jsp. Accessed July 2013."},{"key":"e_1_2_6_4_1","volume-title":"Altoprev [product information]","author":"Andrx Labs","year":"2012"},{"key":"e_1_2_6_5_1","volume-title":"Penicillin G potassium injection [product information]","author":"Baxter Healthcare","year":"2012"},{"key":"e_1_2_6_6_1","volume-title":"Thiotepa [product information]","author":"Bedford Laboratories","year":"2001"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020887"},{"key":"e_1_2_6_8_1","volume-title":"Health risks related to high intake of preformed retinol (vitamin A) in the Nordic countries","author":"Blomhoff R","year":"2003"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20223"},{"key":"e_1_2_6_10_1","volume-title":"Drugs in pregnancy and lactation","author":"Briggs GG","year":"2011"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/026119290203000205"},{"key":"e_1_2_6_12_1","unstructured":"Caffeine Pharmacology. n.d.Medscape web site. Available athttp:\/\/reference.medscape.com\/drug\/cafcit\u2010nodoz\u2010caffeine\u2010342995#10. Accessed August 2011."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2005.12.069"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2009.05.002"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0355"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-08-046884-6.01503-7"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20276"},{"key":"e_1_2_6_18_1","volume-title":"Amoxil [product information]","author":"Dr Reddy's Laboratories","year":"2011"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2003.00462.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3000"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/026119290403200305"},{"key":"e_1_2_6_22_1","volume-title":"Vistide [product information]","author":"Gilead Sciences","year":"2000"},{"key":"e_1_2_6_23_1","volume-title":"Hepsera [product information]","author":"Gilead Sciences","year":"2012"},{"key":"e_1_2_6_24_1","volume-title":"Agenerase [product information]","author":"GlaxoSmithKline","year":"2005"},{"key":"e_1_2_6_25_1","volume-title":"Avandia [product information]","author":"GlaxoSmithKline","year":"2011"},{"key":"e_1_2_6_26_1","volume-title":"Ziagen [product information]","author":"GlaxoSmithKline","year":"2012"},{"key":"e_1_2_6_27_1","volume-title":"Tykerb [product information]","author":"GlaxoSmithKline","year":"2013"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2011.12.004"},{"key":"e_1_2_6_29_1","first-page":"12A","article-title":"Folates in reproduction: in vitro studies","volume":"51","author":"Hansen DK","year":"1995","journal-title":"Teratology"},{"key":"e_1_2_6_30_1","first-page":"420","article-title":"Effect of dietary supplementation with folic acid on valproate\u2010induced neural tube defects","volume":"47","author":"Hansen DK","year":"1993","journal-title":"Teratology"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrc.20085"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000086879"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0887-2333(95)00012-W"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1987.tb03090.x"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-2587"},{"key":"e_1_2_6_36_1","unstructured":"Isoniazid (Systemic). n.d.Drugs.com Web site. Available at:http:\/\/www.drugs.com\/mmx\/isoniazid.html. Updated June 30 2000. Accessed August 2011."},{"key":"e_1_2_6_37_1","first-page":"624","article-title":"Prediction of risk for human developmental toxicity: how important are animal studies for hazard identification?","volume":"74","author":"Jelovsek FR","year":"1989","journal-title":"Obset Gynecol"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.nutr.28.061807.155333"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005283461"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2011.08.025"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00348315"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00316367"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrc.20081"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20005"},{"key":"e_1_2_6_45_1","first-page":"211","article-title":"Pharmacokinetic interaction study between ranitidine and metoclopramide","volume":"13","author":"Leucu\u0163a A","year":"2004","journal-title":"Rom J Gastroenterol"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20123"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2011.02.012"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1989.tb03323.x"},{"key":"e_1_2_6_49_1","first-page":"212","article-title":"The toxicity potential of pharmaceuticals found in the Douro River estuary (Portugal)\u2013experimental assessment using a zebrafish embryo test","volume":"32","author":"Madureira TV","year":"2011","journal-title":"Environ Toxicol Pharmacol"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00668.x"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2950641"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/026119290903700314"},{"key":"e_1_2_6_53_1","volume-title":"Aquasol A [product information]","author":"Mayne Pharma"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2008.03.002"},{"key":"e_1_2_6_55_1","volume-title":"Tylenol [Product Information]","author":"McNeil Consumer Healthcare","year":"2010"},{"key":"e_1_2_6_56_1","volume-title":"Cuprimine [product information]","author":"Merck","year":"2004"},{"key":"e_1_2_6_57_1","volume-title":"Januvia [product information]","author":"Merck","year":"2013"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-255"},{"key":"e_1_2_6_59_1","first-page":"2138","article-title":"Clinical pharmacology of oral all\u2010trans retinoic acid in patients with acute promyelocytic leukemia","volume":"52","author":"Muindi JR","year":"1992","journal-title":"Cancer Res"},{"key":"e_1_2_6_60_1","volume-title":"Scientific frontiers in developmental toxicology and risk assessment","author":"National Research Council (NRC)","year":"2000"},{"key":"e_1_2_6_61_1","volume-title":"Toxicity testing in the 21st century. A vision and a strategy","author":"National Research Council (NRC)","year":"2007"},{"key":"e_1_2_6_62_1","volume-title":"Comtan [product information]","author":"Novartis Pharmaceuticals","year":"2010"},{"key":"e_1_2_6_63_1","volume-title":"Everolimus [product information]","author":"Novartis Sverige AB","year":"2011"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-1012-5"},{"key":"e_1_2_6_65_1","volume-title":"Busulfex [product information]","author":"Otsuka America Pharmaceutical","year":"2011"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-7-200404060-00010"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.06.007"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20148"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/iub.230"},{"key":"e_1_2_6_70_1","volume-title":"Dilantin [product information]","author":"Pfizer","year":"2012"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/0890-6238(95)00009-Y"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.10054"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v012.i05"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfq292"},{"key":"e_1_2_6_75_1","volume-title":"Accutane [product information]","author":"Roche Laboratories","year":"2010"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2013.02.020"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2011.08.003"},{"key":"e_1_2_6_78_1","volume-title":"Catalog of teratogenic agents","author":"Shepard TH","year":"2007"},{"key":"e_1_2_6_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-007-0582-y"},{"key":"e_1_2_6_80_1","first-page":"30831","article-title":"Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling","volume":"73","author":"Shuren J","year":"2008","journal-title":"Fed Regist"},{"key":"e_1_2_6_81_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac051437y"},{"key":"e_1_2_6_82_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0022-3565(25)12789-4","article-title":"Dysmorphogenesis elicited by microinjected acetaminophen analogs and metabolites in rat embryos cultured in vitro","volume":"255","author":"Stark KL","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_83_1","doi-asserted-by":"publisher","DOI":"10.4103\/0975-7406.94808"},{"key":"e_1_2_6_84_1","unstructured":"Teratogen Information System (TERIS).2013.Web site. Available at:http:\/\/depts.washington.edu\/terisweb\/teris\/. Accessed July 2013."},{"key":"e_1_2_6_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420350215"},{"key":"e_1_2_6_86_1","unstructured":"Thalidomide Pharmacology. n.d.Medscape web site. Available at:http:\/\/reference.medscape.com\/drug\/thalomid\u2010thalidomide\u2010343211#10. Accessed August 2011."},{"key":"e_1_2_6_87_1","doi-asserted-by":"publisher","DOI":"10.2741\/4032"},{"key":"e_1_2_6_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20289"},{"key":"e_1_2_6_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2010.10.017"},{"key":"e_1_2_6_90_1","first-page":"246","article-title":"Comparative bioavailability of two oral l\u2010thyroxine formulations after multiple dose administration in patients with hypothyroidism and its relation with therapeutic endpoints and dissolution profiles","volume":"51","author":"Vaisman M","year":"2001","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100075"},{"key":"e_1_2_6_92_1","volume-title":"Sarafem [product information]","author":"Warner Chilcott","year":"2013"},{"key":"e_1_2_6_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2011.01.004"},{"key":"e_1_2_6_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V59.6.1351.1351"},{"key":"e_1_2_6_95_1","first-page":"103","article-title":"Bioavailability of warfarin from three tablet preparations","volume":"42","author":"Welle\u2010Watne A","year":"1980","journal-title":"Medd Norsk Farm Selsk"},{"key":"e_1_2_6_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2010.05.007"},{"key":"e_1_2_6_97_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfs112"}],"container-title":["Birth Defects Research Part B: Developmental and Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdrb.21078","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdrb.21078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T16:46:58Z","timestamp":1746031618000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdrb.21078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1002\/bdrb.21078"],"URL":"https:\/\/doi.org\/10.1002\/bdrb.21078","archive":["Portico"],"relation":{},"ISSN":["1542-9733","1542-9741"],"issn-type":[{"value":"1542-9733","type":"print"},{"value":"1542-9741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}